Brain Scientific INC.: directors' dealings · United States · SEC (Form 4)

About Brain Scientific INC.

Brain Scientific Inc. is a United States-based medtech company listed in the U.S. public markets on NASDAQ, and it operates within the healthcare device universe. Historically, the company has been focused on neurodiagnostic technology, with a mission centered on making brain monitoring more accessible through simplified EEG data capture, analysis, and sharing. Over time, Brain Scientific has gone through structural and strategic changes, including a corporate name change in 2018 and a later operational refocusing around technology platforms and intellectual property assets. SEC filings show that the company has operated from the New York area in earlier periods and from Lakewood Ranch, Florida in more recent filings, underscoring a U.S. management base and a comparatively small physical footprint. The business is built around two complementary product lines. On the neurology side, the company’s Memory MD subsidiary has developed NeuroCap and NeuroEEG, portable, non-invasive EEG solutions designed to streamline brain signal acquisition. These products are aimed at neurologists, specialty clinics, hospitals, and tele-neurology workflows. On the precision motion side, Piezo Motion develops small piezoelectric motors intended for medical devices and other applications that require compact, high-precision actuation. This gives Brain Scientific an unusual profile: a neurodiagnostics platform on one side and a precision component business on the other. From a competitive standpoint, Brain Scientific operates in a market where value is driven by portability, faster diagnosis, telemedicine compatibility, and lower per-test cost. Its differentiation has historically rested on easier-to-deploy EEG devices and a portfolio of patents rather than on large-scale commercial reach. The company has previously highlighted FDA-cleared products, which is important for clinical credibility, but investors should view it as a small-cap healthcare name on NASDAQ with limited commercial scale relative to major neurology equipment manufacturers. One of the most important recent developments is that Brain Scientific announced FDA clearance for a next-generation NeuroCap device in 2021. More recently, however, SEC-related disclosures and third-party filings indicate that a portfolio of EEG brain-monitoring assets formerly associated with Brain Scientific was acquired by Aditxt in January 2024. That development suggests a meaningful change in the company’s operating perimeter and makes strategic continuity a key point to monitor. For French, Belgian, and Swiss investors, Brain Scientific should be assessed as a speculative small-cap healthcare and medical technology story rather than a mature operating company. The investment case depends on execution, regulatory status, commercialization of remaining assets, and the company’s ability to preserve or monetize intellectual property. Given the limited scale and the recent asset transfer, the name carries elevated operational and disclosure risk, and it is best framed as an early-stage or transitional NASDAQ-listed U.S. medtech company.